Analysis of The Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasm in 70 Cases_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 GONGHai-yan ¹ , GEWei ² , JIANGSong-song ² ,  CHENGang ²

1. Department of Physical Examination Center, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu Province, China;
2. Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu Province, China;

Corresponding?author：

CHENGang, Email: gulou_hospital@163.com

Keywords：

Gastroenteropancreatic neuroendocrine neoplasm; Diagnosis; Treatment; Carcinoid

DOI：

10.7507/1007-9424.20140274

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summary the pathogenic site, clinical manifestations, endoscopic and radiographic features, pathologic characteristics, diagnosis, treatment, and prognosis of gastroenteropancreatic neuroendocrine neoplasm(GEP-NEN). Methods Clinical data of 70 cases of GEP-NEN who were treated in Nanjing Drum Tower Hospital from Jan. 2003 to Dec. 2012 were collected and retrospectively analyzed. Results Of the 70 cases, 35 cases(50.0%) were in pancreas, 18 cases(25.7%) were in rectum, 10 cases(14.3%) were in stomach, and 7 cases(10.0%) were in appendix; 55 cases(78.6%) were nonfunctional tumors, while 15 cases(21.4%) were functional; 50 cases(71.4%) were neuroendocrine tumor, 15 cases(21.4%) were neuroendocrine carcinoma, and 5 cases(7.2%) were mixed adenoendocrine carcinoma; 43 cases(61.4%) were in grade 1, 7 cases(10.0%) were in grade 2, and 20 cases(28.6%) were in grade 3 respectively. The detection rate of endoscopy, type-B ultrasonic, CT, and MRI were 90.0%(27/30), 67.9% (19/28), 86.0%(43/50), and 70.0%(7/10) respectively. A total of 67 patients(95.7%) were underwent surgery, including endoscopic resection, and 3 cases (4.3%) didn't receive surgery. Forty cases were followed-up for 6 months to 9 years(the median survival time was 3 years), and the 1-, 3-, and 5-year survival rates were 82.5%(33/40), 47.5%(19/40), and 35.0%(14/40) respectively. Conclusion GEP-NEN occurs mainly in pancreas, and the clinical manifestations are variable. Endoscopy and radiographic examination methods play an important role in diagnosis of GEP-NEN, but final diagnosis is mainly based on pathological detection. Surgery is the main treatment method for it.

Citation： GONGHai-yan, GEWei, JIANGSong-song, CHENGang. Analysis of The Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasm in 70 Cases. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(9): 1145-1148. doi: 10.7507/1007-9424.20140274 Copy

1.	Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumors of the digestive system[M]. 4th ed. Lyon:IARC Press, 2010:2-5.
2.	中國胃腸胰神經內分泌腫瘤病理專家組. 中國胃腸胰神經內分泌腫瘤病理學診斷共識[J]. 中華病理學雜志, 2011, 40(4):257-262.
3.	Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13715 carcinoid tumors[J]. Cancer, 2003, 97(4):934-959.
4.	Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid":epidemiology of and prognostic factors for neuroendocrine tumors in 35825 cases in the United States[J]. J Clin Oncol, 2008, 26(18):3063-3072.
5.	Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors:application of the Delphic consensus process to the development of a minimum pathology data set[J]. Am J Surg Pathol, 2010, 34(3):300-313.
6.	Toth-Fejel SE, Pommier RF. Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors[J]. Am J Surg, 2004, 187(5):575-579.
7.	Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors[J]. Digestion, 2000, 62 Suppl 1:33-38.
8.	楊曉鷗, 錢家鳴, 李景南. 血漿嗜鉻粒蛋白A對胃腸胰腺內分泌腫瘤的診斷價值[J]. 胃腸病學, 2008, 13(4):205-208.
9.	Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines well-differentiated neuroendocrine tumors of the stomach and pancreas[J]. Pancreas, 2010, 39(6):735-752.
10.	王鈺虹, 林原, 薛玲, 等. 87例胃腸胰神經內分泌腫瘤的診治分析[J]. 中華消化雜志, 2011, 31(8):531-535.
11.	蓋保東, 肖鐘迪. 胃腸胰腺神經內分泌腫瘤診治進展[J]. 中華內分泌外科雜志, 2009, 3(2):76-79.
12.	劉曦嬌, 王威亞, 黃子星, 等. 胰腺神經內分泌癌的影像學表現[J]. 中國普外基礎與臨床雜志, 2012, 19(10):1126-1129.
13.	何云飛, 馮仕庭, 李子平. 胃腸胰神經內分泌腫瘤的影像診斷進展[J]. 國際醫學放射學雜志, 2012, 35(1):53-58.
14.	Meyer T, Qian W, Caplin ME, et al. Capecitabine and streptozocin±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours[J]. Eur J Cancer, 2014, 50(5):902-911.
15.	Kamp K, Gumz B, Feelders RA, et al. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate[J]. Endocr Relat Cancer, 2013, 20(6):825-831.
16.	Meeker A, Heaphy C. Gastroenteropancreatic endocrine tumors[J]. Mol Cell Endocrinol, 2014, 386(1-2):101-120.
17.	Grande E, Díez JJ, Pachón V, et al. Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)[J]. Clin Transl Oncol, 2010, 12(7):481-492.
18.	Oberg K, Akerstr?m G, Rindi G, et al. Neuroendocrine gastroenteropancreatic tumours:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2010, 21 Suppl 5:v223-v227.
19.	陳曦, 周光文. 胰腺神經內分泌腫瘤診治熱點探討[J]. 中國普外基礎與臨床雜志, 2012, 19(10):1033-1038.
20.	楊春明. 常見胰腺神經內分泌腫瘤的診斷和治療[J]. 中國普外基礎與臨床雜志, 2012, 19(10):1029-1032.
21.	Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6):501-513.
22.	Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6):514-523.
23.	Cho MY, Sohn JH, Jin SY, et al. Proposal for a standardized pathology report of gastroenteropancreatic neuroendocrine tumors:prognostic significance of pathological parameters[J]. Korean J Pathol, 2013, 47(3):227-237.
24.	2013年中國胃腸胰神經內分泌腫瘤病理診斷共識專家組. 中國胃腸胰神經內分泌腫瘤病理診斷共識(2013版)[J]. 中華病理學雜志, 2013, 42(10):691-694.
25.	Ter-Minassian M, Chan JA, Hooshmand SM, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors:results from a prospective institutional database[J]. Endocr Relat Cancer, 2013, 20(2):187-196.

1. Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumors of the digestive system[M]. 4th ed. Lyon:IARC Press, 2010:2-5.
2. 中國胃腸胰神經內分泌腫瘤病理專家組. 中國胃腸胰神經內分泌腫瘤病理學診斷共識[J]. 中華病理學雜志, 2011, 40(4):257-262.
3. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13715 carcinoid tumors[J]. Cancer, 2003, 97(4):934-959.
4. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid":epidemiology of and prognostic factors for neuroendocrine tumors in 35825 cases in the United States[J]. J Clin Oncol, 2008, 26(18):3063-3072.
5. Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors:application of the Delphic consensus process to the development of a minimum pathology data set[J]. Am J Surg Pathol, 2010, 34(3):300-313.
6. Toth-Fejel SE, Pommier RF. Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors[J]. Am J Surg, 2004, 187(5):575-579.
7. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors[J]. Digestion, 2000, 62 Suppl 1:33-38.
8. 楊曉鷗, 錢家鳴, 李景南. 血漿嗜鉻粒蛋白A對胃腸胰腺內分泌腫瘤的診斷價值[J]. 胃腸病學, 2008, 13(4):205-208.
9. Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines well-differentiated neuroendocrine tumors of the stomach and pancreas[J]. Pancreas, 2010, 39(6):735-752.
10. 王鈺虹, 林原, 薛玲, 等. 87例胃腸胰神經內分泌腫瘤的診治分析[J]. 中華消化雜志, 2011, 31(8):531-535.
11. 蓋保東, 肖鐘迪. 胃腸胰腺神經內分泌腫瘤診治進展[J]. 中華內分泌外科雜志, 2009, 3(2):76-79.
12. 劉曦嬌, 王威亞, 黃子星, 等. 胰腺神經內分泌癌的影像學表現[J]. 中國普外基礎與臨床雜志, 2012, 19(10):1126-1129.
13. 何云飛, 馮仕庭, 李子平. 胃腸胰神經內分泌腫瘤的影像診斷進展[J]. 國際醫學放射學雜志, 2012, 35(1):53-58.
14. Meyer T, Qian W, Caplin ME, et al. Capecitabine and streptozocin±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours[J]. Eur J Cancer, 2014, 50(5):902-911.
15. Kamp K, Gumz B, Feelders RA, et al. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate[J]. Endocr Relat Cancer, 2013, 20(6):825-831.
16. Meeker A, Heaphy C. Gastroenteropancreatic endocrine tumors[J]. Mol Cell Endocrinol, 2014, 386(1-2):101-120.
17. Grande E, Díez JJ, Pachón V, et al. Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)[J]. Clin Transl Oncol, 2010, 12(7):481-492.
18. Oberg K, Akerstr?m G, Rindi G, et al. Neuroendocrine gastroenteropancreatic tumours:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2010, 21 Suppl 5:v223-v227.
19. 陳曦, 周光文. 胰腺神經內分泌腫瘤診治熱點探討[J]. 中國普外基礎與臨床雜志, 2012, 19(10):1033-1038.
20. 楊春明. 常見胰腺神經內分泌腫瘤的診斷和治療[J]. 中國普外基礎與臨床雜志, 2012, 19(10):1029-1032.
21. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6):501-513.
22. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6):514-523.
23. Cho MY, Sohn JH, Jin SY, et al. Proposal for a standardized pathology report of gastroenteropancreatic neuroendocrine tumors:prognostic significance of pathological parameters[J]. Korean J Pathol, 2013, 47(3):227-237.
24. 2013年中國胃腸胰神經內分泌腫瘤病理診斷共識專家組. 中國胃腸胰神經內分泌腫瘤病理診斷共識(2013版)[J]. 中華病理學雜志, 2013, 42(10):691-694.
25. Ter-Minassian M, Chan JA, Hooshmand SM, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors:results from a prospective institutional database[J]. Endocr Relat Cancer, 2013, 20(2):187-196.

Previous Article
Clinical Research on The Intra-Abdominal Infection after Pancreaticoduodenectomy
Next Article
Relationship of Recurrent Laryngeal Nerve Injury with Surgical Approach

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Analysis of The Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasm in 70 Cases

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content